JPH11507352A5 - - Google Patents

Info

Publication number
JPH11507352A5
JPH11507352A5 JP1997501850A JP50185097A JPH11507352A5 JP H11507352 A5 JPH11507352 A5 JP H11507352A5 JP 1997501850 A JP1997501850 A JP 1997501850A JP 50185097 A JP50185097 A JP 50185097A JP H11507352 A5 JPH11507352 A5 JP H11507352A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP1997501850A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11507352A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1996/009553 external-priority patent/WO1996040726A1/en
Publication of JPH11507352A publication Critical patent/JPH11507352A/ja
Publication of JPH11507352A5 publication Critical patent/JPH11507352A5/ja
Withdrawn legal-status Critical Current

Links

JP9501850A 1995-06-07 1996-06-05 新規カルバメート基本カチオン性脂質 Withdrawn JPH11507352A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48346595A 1995-06-07 1995-06-07
US08/483,465 1995-06-07
PCT/US1996/009553 WO1996040726A1 (en) 1995-06-07 1996-06-05 Novel carbamate-based cationic lipids

Publications (2)

Publication Number Publication Date
JPH11507352A JPH11507352A (ja) 1999-06-29
JPH11507352A5 true JPH11507352A5 (enExample) 2004-07-29

Family

ID=23920143

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9501850A Withdrawn JPH11507352A (ja) 1995-06-07 1996-06-05 新規カルバメート基本カチオン性脂質

Country Status (6)

Country Link
US (2) US6251939B1 (enExample)
EP (1) EP0830368A1 (enExample)
JP (1) JPH11507352A (enExample)
AU (1) AU701106B2 (enExample)
CA (1) CA2223088A1 (enExample)
WO (1) WO1996040726A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2223179A1 (en) * 1995-06-07 1996-12-19 Bob Dale Brown Phosphonic acid-based cationic lipids
AU2911197A (en) * 1996-05-24 1998-01-05 Imperial College Of Science, Technology And Medicine Polycationic sterol derivatives as transfection agents
WO2004089973A2 (en) * 1997-01-23 2004-10-21 Epimmune Inc. Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
FR2760193B1 (fr) * 1997-02-28 1999-05-28 Transgene Sa Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules
US5877220A (en) * 1997-03-06 1999-03-02 Genta, Incorporated Amide-based oligomeric cationic lipids
US6034135A (en) * 1997-03-06 2000-03-07 Promega Biosciences, Inc. Dimeric cationic lipids
US5925628A (en) * 1997-03-31 1999-07-20 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5912239A (en) * 1997-04-04 1999-06-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
US5948925A (en) * 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5952516A (en) * 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
CA2299429C (en) 1997-08-13 2010-04-20 Biontex Laboratories Gmbh New lipopolyamines,their preparation and the use thereof
CN101041079A (zh) * 1999-12-30 2007-09-26 诺瓦提斯公司 用于基因治疗的新的胶体合成载体
GB0015624D0 (en) * 2000-06-26 2000-08-16 Nat Cancer Centre Materials and methods relating to improved gene delivery
US6777443B2 (en) * 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
US20040161741A1 (en) * 2001-06-30 2004-08-19 Elazar Rabani Novel compositions and processes for analyte detection, quantification and amplification
CN100415227C (zh) * 2001-10-25 2008-09-03 阿特罗吉尼克斯公司 化合物在制备用于治疗移植排斥的药物中的应用
GB0129121D0 (en) * 2001-12-05 2002-01-23 Ic Vec Ltd Compound
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
CN1882693B (zh) * 2003-09-15 2012-08-15 普洛体维生物治疗公司 聚乙二醇修饰的脂质化合物及其应用
ATE536418T1 (de) * 2004-06-07 2011-12-15 Protiva Biotherapeutics Inc Lipidverkapselte interferenz-rna
US20060134189A1 (en) * 2004-11-17 2006-06-22 Protiva Biotherapeutics, Inc siRNA silencing of apolipoprotein B
WO2007051303A1 (en) 2005-11-02 2007-05-10 Protiva Biotherapeutics, Inc. MODIFIED siRNA MOLECULES AND USES THEREOF
JP5697988B2 (ja) * 2007-12-27 2015-04-08 プロチバ バイオセラピューティクス インコーポレイティッド 干渉ｒｎａを使用したポロ様キナーゼ発現のサイレンシング方法
JP5749494B2 (ja) * 2008-01-02 2015-07-15 テクミラ ファーマシューティカルズ コーポレイション 核酸の送達のための改善された組成物および方法
NZ588583A (en) 2008-04-15 2012-08-31 Protiva Biotherapeutics Inc Novel lipid formulations for nucleic acid delivery
EP2326331A4 (en) * 2008-08-18 2013-05-15 Merck Sharp & Dohme NEW LIPID NANOPARTICLES AND NEW COMPONENTS FOR THE RELEASE OF NUCLEIC ACIDS
JP5777519B2 (ja) 2008-10-09 2015-09-09 テクミラ ファーマシューティカルズ コーポレイション 改良されたアミノ脂質および核酸の送達方法
EP4241767B1 (en) * 2008-11-10 2024-10-23 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
WO2010083615A1 (en) 2009-01-26 2010-07-29 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein c-iii expression
US8283333B2 (en) 2009-07-01 2012-10-09 Protiva Biotherapeutics, Inc. Lipid formulations for nucleic acid delivery
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2011011447A1 (en) 2009-07-20 2011-01-27 Protiva Biotherapeutics, Inc. Compositions and methods for silencing ebola virus gene expression
WO2011071860A2 (en) * 2009-12-07 2011-06-16 Alnylam Pharmaceuticals, Inc. Compositions for nucleic acid delivery
US8455455B1 (en) 2010-03-31 2013-06-04 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes involved in hemorrhagic fever
WO2011143230A1 (en) * 2010-05-10 2011-11-17 Alnylam Pharmaceuticals Methods and compositions for delivery of active agents
US20130123338A1 (en) * 2010-05-12 2013-05-16 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
US10077232B2 (en) * 2010-05-12 2018-09-18 Arbutus Biopharma Corporation Cyclic cationic lipids and methods of use
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
EP4295895A3 (en) 2017-05-11 2024-03-27 Tc1 Llc Thermal interconnect for implantable blood pump
CA3200234A1 (en) 2020-11-25 2022-06-02 Daryl C. Drummond Lipid nanoparticles for delivery of nucleic acids, and related methods of use
WO2023196444A1 (en) * 2022-04-05 2023-10-12 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
EP4531819A2 (en) 2022-05-25 2025-04-09 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3649674A (en) * 1967-08-25 1972-03-14 Schering Ag Salts of carbamic and thiocarbamic esters with fungicidal and fungistatic action
US4007281A (en) * 1971-04-16 1977-02-08 Colgate-Palmolive Company Pharmaceutical compositions containing quaternary ammonium compounds
ES506955A0 (es) 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA1252778A (en) * 1983-08-25 1989-04-18 Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee Steroids
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
WO1986005519A1 (en) 1985-03-15 1986-09-25 James Summerton Polynucleotide assay reagent and method
EP0248819B2 (en) 1985-09-12 2000-08-30 Scios Inc. Recombinant fibroblast growth factors
JP3134874B2 (ja) 1986-08-21 2001-02-13 ザ・トラステイーズ・オブ・コロンビア・ユニヴアーシテイ・イン・ザ・シテイ・オブ・ニユー・ヨーク Ｔ細胞表面タンパク質ｔ４をコードするｄｎａ並びにｔ４フラグメントのａｉｄｓ治療への使用
WO1989001940A1 (en) 1987-09-04 1989-03-09 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing soluble t4 proteins
WO1989008114A1 (en) 1988-02-25 1989-09-08 The General Hospital Corporation Rapid immunoselection cloning method
AU3534989A (en) * 1988-04-08 1989-11-03 Scripps Clinic And Research Foundation Polypeptides stabilized by covalent hydrogen bond replacements
JP2826826B2 (ja) * 1988-04-11 1998-11-18 日本ケミファ株式会社 アルキレンジアミン誘導体
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US4936868A (en) * 1988-07-29 1990-06-26 Shell Oil Company Fuel composition
FR2645866B1 (fr) * 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
KR920701230A (ko) 1989-06-05 1992-08-11 원본미기재 엑소뉴클레아제-내성 올리고뉴클레오티드 및 그 제조방법
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
KR920702409A (ko) 1989-10-24 1992-09-04 원본미기재 새로운 결합을 갖는 올리고뉴클레오티드 유사체
DK0942000T3 (da) 1989-10-24 2004-11-01 Isis Pharmaceuticals Inc 2'-modificerede oligonukleotider
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5214136A (en) 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
AU7579991A (en) 1990-02-20 1991-09-18 Gilead Sciences, Inc. Pseudonucleosides and pseudonucleotides and their polymers
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991018997A1 (en) 1990-05-25 1991-12-12 Gilead Sciences, Inc. Sequence-specific nonphotoactivated crosslinking agents which bind to the major groove of duplex dna
DE69126530T2 (de) 1990-07-27 1998-02-05 Isis Pharmaceutical, Inc., Carlsbad, Calif. Nuklease resistente, pyrimidin modifizierte oligonukleotide, die die gen-expression detektieren und modulieren
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
EP0549686A4 (en) 1990-09-20 1995-01-18 Gilead Sciences Inc Modified internucleoside linkages
WO1992009705A1 (en) 1990-11-23 1992-06-11 Gilead Sciences, Inc. Triplex-forming oligomers containing modified bases
WO1992014843A1 (en) 1991-02-21 1992-09-03 Gilead Sciences, Inc. Aptamer specific for biomolecules and method of making
DK51092D0 (da) 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
WO1993009127A1 (en) 1991-11-07 1993-05-13 Gilead Sciences, Inc. Enhanced triple-helix formation directed by oligonucleotides composed of 2'-deoxy-7-deazaxanthosine and 2'-deoxy-7-deazaguanosine and related analogs
EP1256589A3 (en) 1991-11-26 2003-09-17 Isis Pharmaceuticals, Inc. Oligomers containing modified pyrimidines
EP0616612A4 (en) 1991-12-12 1995-01-11 Gilead Sciences Inc NUCLEASE-STABLE OLIGOMERS SUITABLE FOR BINDING AND METHODS OF USE.
US5336615A (en) 1992-01-06 1994-08-09 Yale University Genetically engineered endothelial cells exhibiting enhanced migration and plasminogen activator activity
JPH05295017A (ja) * 1992-04-21 1993-11-09 Dai Ichi Kogyo Seiyaku Co Ltd カルバメート基を有する共重合体、その製造方法及び該共重合体を含有する熱可塑性樹脂組成物
AU4525093A (en) 1992-05-28 1993-12-30 Gilead Sciences, Inc. Conformationally restrained oligomers containing amide or carbamate linkages for sequence-specific binding
US5817781A (en) 1992-06-01 1998-10-06 Gilead Sciences, Inc. Modified internucleoside linkages (II)
WO1993024640A2 (en) 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
CA2135313A1 (en) 1992-06-18 1994-01-06 Theodore Choi Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
AU6014094A (en) 1992-12-02 1994-06-22 Baylor College Of Medicine Episomal vectors for gene therapy
AU6045094A (en) * 1993-02-19 1994-09-14 Nippon Shinyaku Co. Ltd. Drug composition containing nucleic acid copolymer
WO1994021807A2 (en) 1993-03-19 1994-09-29 Cantab Pharmaceuticals Research Limited Defective mutant non-retroviral virus (e.g. hsv) as vaccine
AU7044994A (en) * 1993-05-24 1994-12-20 Nycomed Pharma Hemoregulatory peptides

Similar Documents

Publication Publication Date Title
JP2000500228A5 (enExample)
JPH11510317A5 (enExample)
JP2000500440A5 (enExample)
JP2000500445A5 (enExample)
JP2000500627A5 (enExample)
JP2000500145A5 (enExample)
JP2000500155A5 (enExample)
JP2000502389A5 (enExample)
JP2001519678A5 (enExample)
JP2000500361A5 (enExample)
JP2000500115A5 (enExample)
JP2000500322A5 (enExample)
JP2000500258A5 (enExample)
JP2000500342A5 (enExample)
JPH11506914A5 (enExample)
JP2000500192A5 (enExample)
JP2000500112A5 (enExample)
JP2000500226A5 (enExample)
JP2000500051A5 (enExample)
JP2000500407A5 (enExample)
JP2000500166A5 (enExample)
JP2000500397A5 (enExample)
JP2000500019A5 (enExample)
JP2000500346A5 (enExample)
JP2000500044A5 (enExample)